Abstract
DNA-sequencing giant Illumina has formed a new company, called Grail, to develop liquid biopsies capable of spotting cancer before symptoms arise. The start-up is working on a low-cost "pan-cancer" test that can detect multiple cancer types early, which it hopes to introduce by 2019.
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for freeCite
CITATION STYLE
APA
Colwell, J. (2016, April 1). Illumina Spin-off to Develop Early-Detection Test. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-NB2016-015
Readers' Seniority
Readers' Discipline
